Vulnerable populations such as the immunocompromised often aren’t able to mount a protective response following vaccination and continue to be at risk of developing Covid-19. With this first global regulatory filing, we are one step closer to providing an additional option to help protect against Covid-19 alongside vaccines. — Mene Pangalos, an executive vice president at AstraZeneca
Vulnerable populations such as the immunocompromised often aren’t able to mount a protective response following vaccination and continue to be at risk of developing Covid-19. With this first global regulatory filing, we are one step closer to providing an additional option to help protect against Covid-19 alongside vaccines. — Mene Pangalos, an executive vice president at AstraZeneca
AstraZeneca Seeks F.D.A. Approval for Covid Antibody Treatment
AstraZeneca said on Tuesday that it had asked the Food and Drug Administration to grant emergency authorization for an antibody treatment to prevent Covid-19 in people who are at high risk of the disease. If authorized, it would become the first such preventive treatment to be available in the United States, the company said.

The company said in a statement that the treatment had reduced the risk of symptomatic Covid-19 by 77 percent in a trial in which most participants either had other medical conditions that placed them at greater risk of severe illness or were not producing sufficient antibodies after vaccination.

It said the treatment could be used in conjunction with vaccines in people with weaker immune systems. Other antibody treatments in use in the United States, including one developed by the drug maker Regeneron, have mainly been used to treat people who are already infected with the coronavirus.

“Vulnerable populations such as the immunocompromised often aren’t able to mount a protective response following vaccination and continue to be at risk of developing Covid-19,” Mene Pangalos, an executive vice president at AstraZeneca, said in a statement. “With this first global regulatory filing, we are one step closer to providing an additional option to help protect against Covid-19 alongside vaccines.”
Read the full article: https://www.nytimes.com/2021/10/05/us/covid-astrazeneca-fda-antibody.html